TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo.
Genital coinfections increase an individual's risk of becoming infected with HIV-1 by sexual contact. Several mechanisms have been proposed to explain this, such as the presence of ulceration and bleeding caused by the coinfecting pathogen. Here we demonstrate that Langerhans cells (LCs) are involved in the increased susceptibility to HIV-1 in the presence of genital coinfections. Although LCs are a target for HIV-1 infection in genital tissues, we found that immature LCs did not efficiently mediate HIV-1 transmission in an ex vivo human skin explant model. However, the inflammatory stimuli TNF-alpha and Pam3CysSerLys4 (Pam3CSK4), the ligand for the TLR1/TLR2 heterodimer, strongly increased HIV-1 transmission by LCs through distinct mechanisms. TNF-alpha enhanced transmission by increasing HIV-1 replication in LCs, whereas Pam3CSK4 acted by increasing LC capture of HIV-1 and subsequent trans-infection of T cells. Genital infections such as Candida albicans and Neisseria gonorrhea not only triggered TLRs but also induced TNF-alpha production in vaginal and skin explants. Thus, during coinfection, LCs could be directly activated by pathogenic structures and indirectly activated by inflammatory factors, thereby increasing the risk of acquiring HIV-1. Our data demonstrate a decisive role for LCs in HIV-1 transmission during genital coinfections and suggest antiinflammatory therapies as potential strategies to prevent HIV-1 transmission.
de Jong
Marein A W P
MA
Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands.
de Witte
Lot
L
Oudhoff
Menno J
MJ
Gringhuis
Sonja I
SI
Gallay
Philippe
P
Geijtenbeek
Teunis B H
TB
D001706:Biopsy; D016207:Cytokines / Q000378:metabolism; D004198:Disease Susceptibility / Q000139:chemically induced; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D005260:Female; D015658:HIV Infections / Q000635:transmission* / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D019169:Jurkat Cells; D007801:Langerhans Cells / Q000187:drug effects* / Q000821:virology*; D055666:Lipopeptides; D009924:Organ Culture Techniques; D010455:Peptides / Q000494:pharmacology*; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D051193:Toll-Like Receptors / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology*; D014621:Vagina / Q000601:surgery; D014779:Virus Replication / Q000187:drug effects
D016207:Cytokines; D055666:Lipopeptides; C508075:Pam(3)CSK(4) peptide; D010455:Peptides; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha
Immunobiology. 1988 May;177(2):158-70
3042614
Blood. 2004 Mar 15;103(6):2170-9
14630806
J Virol. 2007 Jul;81(13):6858-68
17442711
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13766-71
11095740
Trends Microbiol. 2002 Nov;10(11):508-14
12419615
J Exp Med. 2004 Nov 15;200(10):1279-88
15545354
J Clin Invest. 2005 Nov;115(11):3256-64
16239964
J Exp Med. 1996 Jan 1;183(1):215-25
8551225
J Biol Chem. 2005 Dec 2;280(48):40293-300
16199531
J Infect Dis. 2007 Nov 15;196(10):1509-16
18008231
Top HIV Med. 2004 Oct-Nov;12(4):104-7
15516707
Anal Biochem. 2004 Jun 15;329(2):293-9
15158490
Eur J Immunol. 2001 Feb;31(2):360-8
11180099
J Virol. 2004 Jul;78(14):7602-9
15220435
Exp Dermatol. 2003 Oct;12(5):700-11
14705812
Curr Opin Immunol. 2004 Aug;16(4):483-7
15245743
AIDS Res Hum Retroviruses. 1989 Apr;5(2):139-46
2785393
J Womens Health (Larchmt). 2003 Jun;12(5):487-94
12869296
Annu Rev Immunol. 2003;21:335-76
12524386
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
12019106
J Virol. 2002 Oct;76(19):9868-76
12208964
Science. 1999 Nov 12;286(5443):1353-7
10558989
J Exp Med. 1994 Dec 1;180(6):2181-90
7964493
Cell. 2007 Dec 14;131(6):1059-71
18083097
Trends Mol Med. 2008 Jan;14(1):12-9
18055263
J Invest Dermatol. 1992 Nov;99(5):48S-50S
1431209
Clin Exp Immunol. 2007 Jan;147(1):176-83
17177977
FEBS Lett. 2001 Jun 1;498(1):116-20
11389909
FEBS Lett. 2005 Jul 4;579(17):3660-8
15963988
J Immunol. 2006 Dec 1;177(11):7959-67
17114468
J Biol Chem. 2003 Nov 21;278(47):46252-60
12966099
J Exp Med. 1995 Jun 1;181(6):2237-47
7760009
J Virol. 2004 Nov;78(21):11980-7
15479838
J Immunol. 2007 Oct 1;179(7):4357-66
17878330
Am J Pathol. 2002 Sep;161(3):867-73
12213715
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40
2494664
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19464-9
18040049
Nat Med. 2007 Mar;13(3):367-71
17334373
Eur J Clin Microbiol Infect Dis. 2004 Sep;23(9):672-6
15322932
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):738-43
16407131
J Acquir Immune Defic Syndr. 2000 May 1;24(1):48-56
10877495
Cell. 1994 Aug 12;78(3):389-98
7914836
Glycoconj J. 2001 Jun;18(6):475-85
12084983
J Immunol. 2007 Feb 15;178(4):1986-90
17277101
Science. 1999 Jul 30;285(5428):736-9
10426996
N Engl J Med. 1997 Apr 10;336(15):1072-8
9091805
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8401-6
12815099
Sex Transm Infect. 1999 Feb;75(1):3-17
10448335
J Virol. 2004 Oct;78(20):10848-55
15452205
J Exp Med. 1998 May 18;187(10):1623-31
9584140
J Dermatol Sci. 2005 Dec;40(3):147-55
16226431
Sex Transm Dis. 1992 Mar-Apr;19(2):61-77
1595015
J Exp Med. 2000 Nov 20;192(10):1491-500
11085750
J Virol. 1991 Mar;65(3):1053-6
1995941